Han Yanqi, Xu Jun, Zhu Qiang, Yang Li, Wang Yitao, Luo Hua, Zhang Tiejun
State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research Co., Ltd, Tianjin, 300462, China.
Anhui Jiren Pharmaceutical Co., Ltd, Bozhou, 236800, Anhui, China.
Chin Med. 2023 Apr 25;18(1):45. doi: 10.1186/s13020-023-00749-1.
Shufeng Jiedu Capsule (SFJDC), composed of eight herbs, is a big brand traditional Chinese medicine (TCM) for the treatment of different respiratory tract infectious diseases with good clinical efficacy and few side effects. It is clinically applied to acute upper respiratory tract infection(URI), influenza, acute exacerbation of chronic obstructive pulmonary disease (AECOPD), community-acquired pneumonia(CAP) and other diseases, due to its antibacterial, antiviral, anti-inflammatory, immunoregulatory and antipyretic activities. In particular, it has shown good clinical effects for COVID-19, and was included in the fourth to tenth editions of the 'Diagnosis and Treatment Protocol for COVID-19 (Trial)' by the National Health Commission. In recent years, studies on the secondary development which focus on the basic and clinical application of SFJDC have been widely reported. In this paper, chemical components, pharmacodynamic material basis, mechanisms, compatibility rule and clinical application were systematically summarized, in order to provide theoretical and experimental basis for further research and clinical application of SFJDC.
疏风解毒胶囊（SFJDC）由八味药材组成，是治疗不同呼吸道传染病的知名品牌中药，临床疗效良好，副作用少。由于其具有抗菌、抗病毒、抗炎、免疫调节和解热作用，临床上适用于急性上呼吸道感染（URI）、流感、慢性阻塞性肺疾病急性加重（AECOPD）、社区获得性肺炎（CAP）等疾病。特别是，它对新型冠状病毒肺炎显示出良好的临床效果，并被国家卫生健康委员会纳入《新型冠状病毒肺炎诊疗方案（试行）》第四至十版。近年来，关于疏风解毒胶囊基础和临床应用的二次开发研究已有广泛报道。本文系统总结了其化学成分、药效物质基础、作用机制、配伍规律及临床应用，为疏风解毒胶囊的进一步研究和临床应用提供理论和实验依据。
